Wednesday, February 01, 2006

Don't Listen to Others

Last week I picked up some Amgen (AMGN) and guess what? It rose 5% today on word that Roche Holdings (RHHBY) has delayed marketing Amgen's generic anemia drug until 2009. And that's assuming they'll receive regulatory approval and prevail against Amgen's patent lawsuit. Again, if you listened to the analysts last week they would have gotten you out of the stock at its low. I bet there are analysts getting ready to upgrade the stock now so they don't look bad. I'm going to hang onto Amgen and not sell for a quick gain. Do your own research, make your own decisions and don't listen to anyone (including me)!


At February 02, 2006, Blogger Mathieu said...

I did a research on how analysts fare, I tracked more than 4 months of Zacks "bull of the day" and put everything in an excel spreadsheet.
(performance for the day-week-month-3months)

The results aren't too bad (going up with time, as zacks set 6 months price target) but they definitely depend on the analyst.

You can download the excel file on my blog

PS : good pick on AMGN


Post a Comment

<< Home